Branford, CT – According to filings with the U.S. Securities and Exchange Commission, Enrich Therapeutics is raising $4,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Dong Wang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Enrich Therapeutics
Enrich Therapeutics was founded in July 2018 and develops a novel cell discovery/isolation technology. Different from any existing fluidics-based technologies, our platform enables a streamlined workflow of natural cell culturing, kinetics profiling, and guided capturing. Enrichs non-fluidic, visual enrichment strategy eliminates the typical pain points of cell-based life science discovery. Our ultimate goal is to allow researchers to obtain the most physiologically meaningful cell clones to increase R&D efficiency unprecedentedly, thereby shortening the cycle of cell therapy and drug discovery tremendously.

To learn more about Enrich Therapeutics, visit http://www.enrichtx.com/

Contact:
Dong Wang, Chief Executive Officer
203-433-4739
dwang@enrichtx.com
https://www.linkedin.com/in/dong-wang-enrichtx/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved